Abeona Therapeutics To Present At Source Capital Group's 2016 Disruptive Growth & Healthcare Conference

DALLAS, TX and NEW YORK, NY--(Marketwired - February 09, 2016) - Abeona Therapeutics, Inc. (ABEO), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that Jeffrey Davis, COO, will be presenting for the company at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference in New York City, NY on Wednesday, February 10th, 2016 at 1:45pm EST on Track 2 in the Murray Hill Hub, along with joining a panel discussion Wednesday, February 10th, 2016 at 3:15pm EST at Convene New York, NY.

Presentation: BIO CEO and Investor Conference
Date: Wednesday, February 10th, 2016
Time: 1:45pm EST
Location: Convene, New York City
Room: Track 2, Murray Hill Hub

Panel Discussion: Immunotherapy Panel
Date: Thursday, February 10th, 2016
Time: 3:15-4pm EST
Location: Track 4 in the Soho Hub

About Source Capital Group

Source Capital Group, Inc. was founded in 1992 on the belief that the best investment advice should be independent, unbiased and tailor-made for the individual client's needs. Source Capital began as a boutique investment banking firm specializing in small to medium sized transactions. We have grown to include businesses in general securities, emerging market securities, distressed and high yield debt securities, in addition to our investment banking activity. http://www.sourcegrp.com/

About Abeona:

Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are AB0-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit www.abeonatherapeutics.com.

Back to news